Dsm International B.V.
disclosed that they own 27.7% of Amyris, Inc. (NASDAQ:AMRS) in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, July 17th. The investor owns 7,936,232 shares of the stock worth approximately $19,285,044. The reporting parties listed on the disclosure included DSM International BV and Koninklijke DSM NV. The filing is available through the SEC website at this link.
Dsm International B.V.
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Separately, Carl Domino Inc increased its position in Amyris by 37.4% in the first quarter. Carl Domino Inc now owns 201,925 shares of the biotechnology company’s stock worth $107,000 after buying an additional 54,925 shares during the last quarter.
Shares of Amyris, Inc. (AMRS) opened at 2.43 on Friday. Amyris, Inc. has a 12 month low of $2.40 and a 12 month high of $18.15. The firm’s market cap is $48.13 million. The company’s 50 day moving average is $3.48 and its 200-day moving average is $5.83.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The company had revenue of $25.68 million for the quarter, compared to analyst estimates of $23.68 million. During the same period last year, the company earned ($0.06) earnings per share. The firm’s revenue for the quarter was up 167.5% compared to the same quarter last year. Equities research analysts predict that Amyris, Inc. will post ($3.98) EPS for the current year.
A number of equities analysts have recently commented on AMRS shares. Zacks Investment Research raised shares of Amyris from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the stock a “buy” rating in a report on Friday. Finally, ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Amyris presently has an average rating of “Hold” and a consensus target price of $31.13.
In other news, Director Patrick Y. Yang acquired 300,000 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The stock was acquired at an average price of $0.29 per share, with a total value of $87,000.00. Following the completion of the transaction, the director now directly owns 153,000 shares of the company’s stock, valued at approximately $44,370. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 11.30% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.